# CancerProbe

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cancerprobe

- Industry: Healthcare Specialists
- Headquarters: Hangzhou, China
- Website: www.cancerprobe.cn
- Total disclosed funding: $14M
- Latest round: Series B (Jul 6, 2020)
- Investors on record: 3

## About

Based in Hangzhou, China and established in 2013, CancerProbe operates as a cancer treatment company which focuses on molecular science and early diagnosis of cancer. In 2014, the company obtained the production license from the State Food and Drug Administration. In July 2020, the firm raised a series B funding for CNY 100 million. Kevin Sun, the founder of the company, has nearly 25 years of global biological research and development experience at Southwest Medical Center, an American biological institution, and Merck, a world-renowned pharmaceutical company.

The company's main products are seven lung cancer-related antibodies. The seven lung cancer-related antibody tests have seven targets, and the seven targets are P53, GAGE 7, PGP9.5, CAGE, MAGE A1, SOX2, and GBU4-5. The company's products are used to detect diseases such as cancer.

The company’s revenue is generated by providing tumor autoantibody detection platform, MicroRNA platform, ct-DNA platform and other detection products.

## Funding rounds

- Series B, Jul 6, 2020, $14M — BOC International (China), Huaxia Hengtian Asset Management
- Series A, Jun 10, 2019 — Zheshang Venture Capital

## Investors

- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Series A
- BOC International (China) (https://capitalatlas.ai/funds/boc-international-china) — Series B
- Huaxia Hengtian Asset Management (https://capitalatlas.ai/funds/huaxia-hengtian-asset-management) — Series B